December 22nd, 2006
Degenerative heart disease
PARIS, Dec. 11 (ANTARA/PRNewswire-AsiaNet) — Boston Scientific Corporation (NYSE: BSX) yesterday presented data on its long-term randomized clinical trials to a special U.S. Food and Drug Administration (FDA) panel, showing that the TAXUS(TM) paclitaxel-eluting coronary stent is as safe as bare-metal stents (BMS), and far more effective in keeping arteries open and reducing the need […]